Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
Sponsor: The First Hospital of Jilin University
Summary
Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of Cadonilimab monotherapy as neoadjuvant therapy for patients with resectable stage II-IIIA squamous cell lung cancer.
Official title: An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
37
Start Date
2023-05-01
Completion Date
2028-05-01
Last Updated
2023-03-27
Healthy Volunteers
No
Conditions
Interventions
Cadonilimab
15 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.